Postpartum Mh Htn denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for postpartum mh htn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Postpartum Mental Health and Hypertension Treatment as Duplicate Therapy

A duplicate-therapy denial for postpartum mental health and hypertension treatment means Humana's utilization management system flagged that a medication or service being requested is considered equivalent to something already approved or dispensed. In the postpartum context, this commonly arises when a patient is transitioning medications from pregnancy to postpartum, receiving coordinated care from both an obstetrician and a mental health provider, or when a new prescription is being issued by a different prescriber while an existing one remains active in the claims system.

This denial is particularly important to challenge promptly because postpartum mental health conditions and hypertension are time-sensitive clinical situations. Inadequately treated postpartum depression, anxiety, or psychosis carries serious risks, and uncontrolled postpartum hypertension can progress to severe maternal morbidity. The clinical stakes make expedited review a realistic and appropriate option.

## Why It Is Appealable

Duplicate-therapy denials are frequently administrative errors. Your appeal should establish that the requested medication or service is clinically distinct from anything already approved — either because it targets a different condition (mental health versus hypertension), because it is a different drug class, because the prior medication was discontinued or is being replaced for a documented clinical reason, or because the two prescriptions are from coordinated providers treating different diagnoses in the same patient.

## Federal Appeal Framework

• Internal appeal (ACA §2719 / ERISA §503): File a written internal appeal within the timeframe on the denial notice. You are entitled to a full-and-fair review by a clinician not involved in the original decision.
• External review (ACA §2719): After exhausting internal appeal, you have approximately four months from the final denial to request independent external review.
• Expedited review: Given the postpartum clinical context, expedited review is strongly advisable. Request it simultaneously with your internal appeal, with a letter from your provider explaining why delay poses a health risk.

## Concrete Appeal Steps and Timeline

1. Ask Humana to identify specifically which approved therapy it considers duplicative of the requested treatment. 2. Have your treating providers document why the requested medication is clinically distinct or why the prior therapy was discontinued. 3. Submit the internal appeal with clinical documentation by the deadline on the denial notice. 4. Request expedited review in writing at the same time. 5. If denied internally, file for external review promptly.

## Documentation to Gather

• Diagnosis confirmation: OB or psychiatry notes confirming postpartum depression, anxiety, psychosis, or postpartum-onset hypertension as distinct, active diagnoses.
• Medication history with dates and outcomes: A complete list of current and recently discontinued medications, with clinical notes explaining why each was started, adjusted, or stopped.
• Prescriber coordination letter: A joint or separate letter from your OB, psychiatrist, or primary care provider explaining the clinical rationale for the requested therapy and why it is not duplicative of any existing approved medication.
• Denial letter details: The exact therapy Humana identified as duplicative, so you can respond specifically.
• Urgency documentation: A provider letter explaining the clinical risks of delaying treatment in the postpartum period.

## Criteria-Mapping Structure

Obtain Humana's published medical/coverage policy and duplicate-therapy criteria for the relevant drug class. List each criterion. For each, provide the specific chart fact showing that the requested therapy addresses a distinct indication, fills a gap in the current regimen, or replaces a discontinued medication for a documented clinical reason. Where two conditions are being treated simultaneously, clearly delineate which provider is managing which diagnosis and why each medication is necessary.